Bionomics Ltd.

OTCQB: BNOEF

Company Logo

Company Overview

Bionomics (ASX: BNO) (OTCQB: BNOEF) is a global, clinical stage biopharmaceutical company leveraging its proprietary platform technologies to discover and develop a deep pipeline of best in class, novel drug candidates. Bionomics’ lead drug candidate BNC210 is a novel, proprietary negative allosteric modulator of the alpha-7 (α7) nicotinic acetylcholine receptor. Beyond BNC210, Bionomics has a strategic partnership with MSD (known as Merck & Co in the US and Canada) and a pipeline of clinical-stage ion channel programs targeting pain, depression, cognition and epilepsy.

Financial Highlights

$0

Revenue (ttm)

-$2,635,298

Gross Profit (ttm)

-$0.04

Diluted EPS (ttm)

Management Team

Dr. Errol B. De Souza
Exec. Chairman

Mr. Adrian Hinton
Acting Chief Financial Officer

Mr. Jack Moschakis B.E., BEc, DipLaw(BAB), GDipBA, FCIS
Legal Counsel & Company Sec.

Prof. Paul Rolan
Consultant Chief Medical Officer of Clinical Neuroscience

Sign Up for Alerts

Receive an email alert every time a company announces a merger, capital raise or files for an IPO.

Company Profile

Website

Twitter

Presentation

Key Highlights

Market Capitalization
$0

Shares Outstanding
0

Shares Short (% of Float)
0 (0%)

Insider Ownership
5%